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For rectal carcinoma, the incidence of local recurrence following
curative resection ranges between 4 and 32% with a median 
of over 15% (Abulati and Williams, 1994). The relatively high inci-
dence of recurrence and poor overall prognosis following appar-
ently curative surgery for rectal carcinoma has led to the increasing
use of adjuvant preoperative radiotherapy in Europe. Most of the
studies (Manchester Trial 1994; Stockholm 1 Trial, 1995; Swedish
Rectal Cancer Trial, 1997) using a higher dose of radiation equiva-
lent to 25 Gy or more, with variable fraction schedules, have
demonstrated a significant reduction in local recurrence compared
with surgery alone. Matrix metalloproteinases (MMPs) are a family
of zinc-containing enzymes (Murphy et al, 1992; Stetler-Stevenson
et al, 1993) involved in the degradation of different components of
the extracellular matrix. There is considerable evidence to indicate
that individual MMPs have important roles in both tumour invasion
and spread (Davies et al, 1993a; Muller et al, 1993; Urbanski et al,
1993; Boag et al, 1994). MMPs have been classified into collage-
nases, gelatinases, stromelysins and the membrane-type MMPs. In
particular, the gelatinases or type-IV collagenases (MMP-2 and
MMP-9) have been implicated in playing a significant proteolytic
role in colorectal cancer invasion and metastasis (Poulson et al,
1992; Pyke et al, 1993; Zucker et al, 1993; Jaziorka et al, 1994). A
moderate increase in the expression of pro MMP-2 during the
adenoma-carcinoma sequence has been reported and contrasts with
the level of active MMP-2, which is absent in normal tissue but
increases dramatically on conversion to the malignant phenotype
(Parsons et al, 1998). This evidence supports the view of other
researchers (Yamagata et al, 1991; Liabakk et al, 1996) that activa-
tion of MMP-2 is a crucial step in tumour invasiveness. It has been
described that poor prognosis in a range of human cancers corre-
lated with increased activity of active MMP-2 and pro MMP-9
(Azzam et al, 1993; Seir et al, 1996). Zeng et al (1996) demon-
strated that levels of MMP-9 were associated with a significant
shorter disease-free and overall survival in patients with colorectal
carcinoma. They also demonstrated that high MMP-9 mRNA
expression progressively increased from early colorectal carcinoma
through invasive and metastatic stages. Their results supported the
observations based on in vitro (Turpeenniemi-Hujanen et al, 1985;
Ballin et al, 1988; Yamagata et al, 1988; Moll et al, 1990) and
animal data (Nakajima et al, 1990) that high tumour MMP-9
expression is associated with increased metastatic potential. There
is considerable evidence suggesting that these enzymes also play a
role in the growth of primary and secondary tumours (reviewed by
Chambers and Matrisian, 1997; Duffy and McCarthy, 1998),
including the process of angiogenesis (Johnson et al, 1994).
In vitro studies have shown that irradiation leads to induction of
MMPs in different types of cell lines (Sheela et al, 1986; Sawaya
et al, 1994). Using gelatin zymography, Sawaya et al (1994)
demonstrated that after single-dose (12 Gy) irradiation of rat astro-
cytes, there was a continuous increase in the levels of pro MMP-2
(72 kDa) at different time intervals, with a significant fivefold
increase at 48 h after irradiation. They proposed that high levels of
MMP-2 along with changes in tissue plasminogen activator (tPA)
may be responsible for radiation-induced damage to the central
nervous system following radiotherapy of brain tumours. These
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Summary The aim of this study was to investigate the effect of preoperative high-dose radiotherapy (25 Gy in 5 fractions over 5 days) on the
type-IV collagenase protein profile, in patients with resectable rectal cancer, by gelatin zymography. Biopsy samples of tumour and distant
normal mucosa from 12 patients with resectable rectal cancer were obtained pre- and post-radiotherapy. Expression of type-IV collagenases
(both pro- and active forms) was studied using gelatin zymography. Enzyme levels were normalized for total protein content of each sample.
Rectal cancer specimens expressed both pro (72 kDa) and active (62 kDa) forms of MMP-2 but only the pro form of MMP-9 (92 kDa). Normal
mucosa showed expression of the pro forms of MMP-2 and MMP-9 while no active form of either enzyme was detected in any of the samples.
A significant three- to fourfold increase (P < 0.01) of active matrix metalloproteinases (MMP)-2 (62 kDa) was seen in malignant rectal mucosa
after radiotherapy. The effect of radiotherapy also led to a twofold increase (P = 0.047) of pro MMP-2 (72 kDa) and a two- to threefold increase
(P = 0.03) of the precursor form of MMP-9 (92 kDa). In contrast, in normal mucosa expression of the precursor form of MMP-9 (92 kDa) did
not change after radiation, and no significant effect on the levels of pro MMP-2 (72 kDa) was observed. Preoperative high-dose radiotherapy
leads to an increase in activity of type-IV collagenases in patients with resectable rectal cancer. Type-IV collagenase inhibition may be a
useful therapeutic adjunct to radiotherapy in rectal cancer. © 2000 Cancer Research Campaign
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radiotherapy leads to overexpression of type-IV collagenases in
rectal cancer. This may be responsible for the promotion of angio-
genesis and in the re-establishment of invasion of remaining viable
cancer cells in an attempt to resurrect the growth potential of the
tumour. The aim of this study was to determine the effect of preop-
erative high-dose short-term radiotherapy (25 Gy in 5 fractions in
5 days) on the type-IV collagenase protein profile of rectal cancer.
PATIENTS AND METHODS
Twelve patients with resectable adenocarcinoma of the rectum,
located within 15 cm from the anal verge, were included in the
study. All patients underwent standard preoperative radiotherapy,
which was delivered to the pelvis with a three-beam technique.
The dose delivered was 25 Gy in 5 fractions over 5 days. Surgery
in the form of anterior resection or abdomino-perineal resection
was performed within a week following completion of the radio-
therapy. This study was carried out with ethical committee
approval and all patients provided written informed consent to
participate in the study.
Tissue samples
Biopsy samples of tumour (n = 24) and distant normal mucosa 
(n = 14) were obtained pre- and post-radiotherapy. Specimens
were obtained from the tumour edge at different sites under vision,
avoiding the necrotic centre. Multiple specimens from the same
tumour were pooled to give a uniform representation of the
tumour. The post-radiotherapy biopsies were performed 48 h after
completion of radiotherapy and just before surgery. The post-
radiotherapy biopsies were taken from sites close to the preradio-
therapy biopsy sites and the normal mucosa was obtained from
within the radiation field. The reason for performing the post-
irradiated biopsy rather than obtaining surgical specimens, was to
eliminate the changes in MMP expression induced by surgical
stress and ischaemia. There were no complications associated with
either biopsy procedure in any of the patients. All tissue samples
were cryopreserved in liquid nitrogen, following their removal
from the patients, and stored at –80°C until use. Ten and 30 micron
cryostat sections were cut from each tissue sample for histology
and electrophoretic analysis respectively. Haematoxylin and eosin
staining was performed on each section to validate the presence of
tumour epithelium and stroma in tumour samples and normal
epithelium. For zymography between 10 and 20 mg of tissue was
used for each sample, as earlier work had shown this quantity of
tissue to give visible bands within the linear range of the zymo-
gram. Sample buffer (sodium dodecyl sulphate (SDS) 100 ml) was
added to each tissue sample in an Eppendorf and homogenized.
The sample was then centrifuged at 16 000 rpm for 5 min and 
25 ml of the supernatant was micropipetted into the wells of a
precast zymogram gel. The remaining sample was used to deter-
mine the protein content. Type IV collagenase levels were
expressed per microgram (mg) of protein.
Gelatin zymography
Gelatin zymography was performed as previously described
(Heussen and Dowdle, 1980; Brown et al, 1993) using commer-
cially available 10% acrylamide precast zymogram gels containing
0.1% gelatin (Novex, GMBA Germany). Pure type-IV collagenase
samples were obtained from British Biotech and prepared from
transfected Chinese hamster ovary cells (Chandler et al, 1995).
Western blotting using monoclonal antibodies for pro and active
MMP-2 and MMP-9 was performed previously to verify that the
bands seen on zymography were as described (data not shown).
All tissue samples were run in duplicate with pre- and post-irradi-
ated samples studied on the same gel to eliminate inter-gel varia-
tion as a source of error when comparing expression of type-IV
collagenases in pre and post radiotherapy tissues. The two outer
lanes contained pure type-IV collagenase (72 kDa and 92 kDa)
standards at 5 ng concentration. After electrophoresis, the gels
were rinsed in 2.5% Triton X-100 for 30 min and incubated at
37°C for 18 h in developing buffer (50 mM Tris–HCl buffer, 
pH 7.5, containing 5 mM calcium chloride, 0.2 M sodium chloride).
The gels were stained with 0.05% colloidal Coomassie blue and
destained in 30% methanol and 10% acetic acid in water.
Gelatinolytic enzymes were detected as transparent bands on the
blue background of the Coomassie-blue-stained slab gel.
Quantification was performed using a flat bed scanner and the
Apple Macintosh software, Adobe Photoshop and NIH Image
Analysis Package as previously described (Davies et al, 1993b;
Kleiner and Stetler-Stevenson, 1994). The bands were scanned in
two positions by densitometry and the peak areas were averaged to
give the enzymatic activity.
Protein determination
The residual 50 ml of each sample was centrifuged at 4°C at 
16 000 rpm for 5 min. The protein was determined in the samples
using a Pierce Kit (Rockford, IL, USA). The standard was bovine
serum albumin (BSA) which was made up in Tris-buffered saline
(TBS, pH 7.6) giving a concentration range of 0.2–1.2 mg per ml.
Buffer, 10 ml of BSA standard or sample was then pipetted into
each well. Protein assay reagent was added (200 ml per well). The
plate was covered and incubated at 37°C for 30 min and the
absorbance read at 562 nm on the plate reader.
Immunocytochemistry
The cellular localization of enzymes was performed using anti-
MMP-2 and anti-MMP-9 (R&D) on all tissue sections.
Statistical analysis
All data was found to be non-parametrically distributed and there-
fore P-values for comparison of enzyme levels were calculated
using the Wilcoxon paired test and the Mann–Whitney U-analysis.
Median values of the enzyme levels were used in these analyses
because of limited sample numbers.
RESULTS
Twelve fresh frozen rectal cancers and seven samples of rectal
mucosa from the same patients, pre- and post-radiotherapy were
evaluated by gelatin zymography. Haematoxylin and eosin
staining confirmed both malignant epithelium and stroma in all the
cancer specimens and normal epithelium and stroma in all the
normal mucosal specimens. Computer-generated image analysis
of malignant or normal epithelium/stroma was performed and the
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ratio was found to be comparable in pre- and post-radiotherapy
sections.
Rectal cancer
All rectal cancers expressed pro MMP-9 (92 kDa) before radio-
therapy. Pro MMP-2 (72 kDa) was detected in 9/12 samples, active
MMP-2 (62 kDa) in 8/12 samples with virtually no expression of
the active MMP-9 (82 kDa) enzyme, preradiotherapy (Table 1).
Figure 1A shows expression of type-IV collagenases in a selected
rectal cancer specimen pre- and post-radiotherapy.
Following radiotherapy, there was a two- to threefold increase in
the levels of pro MMP-9 and this difference was statistically
significant (P = 0.03, Figure 2). No sample showed detectable
levels of active MMP-9, either pre- or post-radiotherapy. Pro
MMP-2 (72 kDa) was found to be expressed in 11 samples as
compared to nine samples, preradiotherapy, with a twofold
increase in the levels (P = 0.042, Figure 2). Post-radiotherapy,
11/12 cancers expressed active MMP-2 (62 kDa) as compared to
8/12 cancers before the radiation treatment. There was three- to
fourfold increase (Figure 2) in the levels of the enzyme (P < 0.01).
Normal mucosa
All seven normal rectal mucosal samples expressed pro MMP-9
enzyme while pro MMP-2 was expressed in 6/7 samples before
radiotherapy. There was virtually no expression of any active form
either before or after the radiotherapy. Figure 1B shows a zymogram
with no active forms of either of type IV collagenases detected.
In contrast to the changes seen in the rectal cancer, radiotherapy
did not affect the expression of pro MMP-9 in normal mucosa
while a non significant reduction in the levels of pro MMP-2 was
observed (P = 0.70).
Immunocytochemistry performed on the tissue sections (Figure
3 A–D) localized the enzymes to the stromal cells rather than the
tumour cells.
DISCUSSION
Surgery remains the primary treatment for rectal cancer and, while
this has become more refined, there is still some debate over the
need for adjuvant treatment. The aim of preoperative high-dose
radiotherapy is to sterilize the resection margins and to destroy
microscopic collections of cancer cells situated outside the
mesorectum, in presacral nodes and at lateral pelvic walls, a poten-
tial focus of local recurrence, and a source of distant metastasis. A
significant number of patients still suffer from local recurrence
(11% in the Swedish Rectal Cancer Trial, 1997) and distant metas-
tasis even after adjuvant radiotherapy.
There is some evidence that irradiation leads to the induction of
type-IV collagenases in vitro (Sheela et al, 1986; Sawaya et al, 1994).
These observations prompted us to investigate whether similar
changes take place in the in vivo situation. Our results demonstrate
that preoperative high-dose radiotherapy leads to a significant
increase in levels of MMP-2 and MMP-9 in rectal cancer tissue, with
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Figure 1 (A) Gelatin zymography of rectal cancer specimens (patient no.
10) showing expression of type-IV collagenases pre- (lanes 2–4) and post-
radiotherapy (lanes 5–7). Lane 1 shows molecular weight standards. 
(B) Gelatin zymography showing expression of type-IV collagenases in pre-
(lanes 2, 3, 6, 7) and post-radiotherapy (anes 4, 5, 8, 9) normal mucosal
specimens. Lanes 1 and 10 show molecular weight standards
Table 1 Levels of type-IV collagenases (measured as square pixels per
microgram of protein) in rectal cancer specimens
Preradiotherapy Post-radiotherapy
MMP expression (kDa) MMP expression (kDa)
Patient 92 82 72 62 92 82 72 62
No
1 51.7 ND 38.2 47.7 219.9 ND 39.6 74.1
2 227.4 ND 55 52.3 61.7 ND 53 53
3 53 ND 21.1 12.6 91.5 ND 61.8 128
4 474.3 ND 304.6 371.3 1817.3 ND 396.5 780
5 390 ND 24 30 578 ND 38 48
6 390 ND ND ND 803 ND 93 414
7 6150 ND 458 408 3465 ND 290 466
8 2312 ND 135 188 5831 ND 384 127
9 711 ND 116 ND 1635 ND 578 163
10 757 ND 116 96 4232 ND 816 750
11 146 ND ND ND 407 ND ND ND
12 278 ND ND ND 1145 ND 31 90
ND, not detected.
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Figure 2 Bar chart comparing median values of 92 kDa (P = 0.03), 72 kDa
(P = 0.047) and 62 kDa (P < 0.01) enzymes (measured as square pixels per
microgram of protein) in pre- and post-radiotherapy rectal cancer specimensMMP-2 and MMP-9 activity following radiotherapy 963
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no increase observed in normal mucosa. A significant three- to
fourfold increase of activated MMP-2 was also seen after radio-
therapy. We have previously demonstrated via gelatin zymography
(Parsons et al, 1998) that it is the active form of MMP-2, which is
associated with the malignant phenotype of colorectal neoplasms.
In another study (Azzam et al, 1993), poor prognosis in breast
cancer correlated not with the expression of pro MMP-2 (72 kDa)
but with its activated form (62 kDa). Localization studies using
immunocytochemistry or in situ hybridization (Poulsom et al,
1992; Pyke et al, 1993; Zeng et al, 1995; Tomita et al, 1996) have
shown that MMP-2 and MMP-9 are localized to the stromal cells at
the growing edge of the tumour rather than in tumour cells them-
selves. It has been suggested (Pyke et al, 1993) that recruitment of
stromal cells to assist cancer cells in the invasive process may be
mediated through signals, in the form of various cytokines, from
the cancer cells. The increased levels of MMP-2 and MMP-9 in
rectal tumour tissue seen after radiotherapy may be due to stromal
activation by cytokines produced by the cancer cells in response to
the treatment. This remains to be determined by future studies which
should include immunocytochemistry to localize type-IV collage-
nase expression in conjunction with cytokines such as TGF-a
and -b, IL-1, TNF-a and EGF. Activation of MMP-2 occurs at the
surface of the cancer cell by membrane type MMP (MT1-MMP)
(Strongin et al, 1995; Kinoshita et al, 1996). The increased activity
of activated MMP-2 seen after adjuvant radiotherapy may be due to
overexpression or activation of MT-1-MMP.
There is considerable evidence to indicate that colorectal
cancers overexpress type-IV collagenases (Zeng et al, 1995;
Liabakk et al, 1996; Parsons et al, 1996; Tomita et al, 1996) and
utilize these enzymes to establish a favourable environment for
growth and invasion. The proteolytic activity of the enzymes helps
the tumour to establish an invasive edge, promoting entry into and
out of blood or lymphatic vessels and expansion of a metastatic
tumour at the secondary site (Chambers and Matrisian, 1997).
Reports have provided strong evidence of a crucial role for MMPs
in the process of tumour angiogenesis (Johnson et al, 1994; Vu et
al, 1998), suggesting another route in which MMPs influence the
growth and behaviour of tumour cells. Mice that lack MMP-9,
show failure of vascularization and apoptosis in the skeletal
growth plate early in development (Vu et al, 1998). When these
mice are crossed with animals in which expression of MMP-9
coincides with activation of an angiogenic switch during tumour
AB
CD
Figure 3 Immunocytochemistry with anti-MMP-2 antibody. (A) Tumour preradiotherapy and (B) tumour post-radiotherapy (magnification ´ 100).
Immunocytochemistry with anti-MMP-9 antibody. (C) Tumour preradiotherapy and (D) tumour post-radiotherapy (magnification ´ 100)formation, loss of MMP-9 suppresses tumorigenesis. This animal
data has revealed evidence linking MMP-9 causally with angio-
genesis. In the present study radiotherapy led to a significant two-
to threefold increase in levels of MMP-9. The MMP inhibitors
TIMP-1 and TIMP-2, which specifically inhibit MMP-9 and
MMP-2 respectively, have been shown to be anti-angiogenic,
strongly suggesting that these two MMPs play an important role in
angiogenesis (Albini et al, 1994).
Our report provides the first evidence that preoperative high-
dose radiotherapy leads to increased type-IV collagenase activity
in rectal cancer. This may be responsible for re-establishing a
blood supply and resurrecting the invasive edge of remaining
viable cancer cells in the pelvis, enhancing the recurrence rate.
Our findings suggest that inhibition of type-IV collagenases may
be a useful therapeutic adjunct to radiotherapy in patients with
resectable rectal cancer, although prospective trials are needed to
determine the actual clinical benefits.
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